Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Adhesion-Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Nectin-3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Nectin-3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View Nectin-3 Products |
| Gene Delivery | Nectin-3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based binding and flow cytometry. |
View Nectin-3 Products |
| Benchmark Ab | Anti-Nectin-3 (Recombinant Positive Control) Sequence-verified benchmark antibody for validation assays. |
View Nectin-3 Products |
| Validator | Nectin-3 siRNA Set For knockdown verification in functional assays. |
View Nectin-3 Products |
| Related Target A | Nectin-4 Key family member overexpressed in urothelial and breast cancers; clinical benchmark for Nectin-targeted ADCs. Essential for Pan-Nectin specificity and counter-screening. |
View Nectin-4 Products |
| Related Target B | Nectin-1 Primary biological binding partner for interaction assays; homophilic/heterophilic adhesion. |
View Nectin-1 Products |
| Related Target C | Nectin-2 Adhesion molecule and immune checkpoint ligand interacting with TIGIT/DNAM-1; synergistic target in tumor immunotherapy. |
View Nectin-2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity |
| Subfamily counter screening / Pan-Nectin selectivity | Homolog panel proteins (Nectin-1, 2, 4) strictly verified by mass spectrometry and sequence analysis |
| ADC Internalization Profiling | HEK293 Expressed (Native Glycosylation) ECD-Fc to preserve native conformational epitopes |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live Nectin-3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Nectin-3 therapeutics is intensifying, fueled by the clinical and commercial success of targeting its family member, Nectin-4 (Enfortumab Vedotin). Nectin-3 (CD113) represents a high-potential, differentiated target. It is frequently overexpressed in challenging solid tumors, including ovarian, breast, pancreatic, and non-small cell lung cancers, while showing limited expression in normal tissues. Nectin-3 mediates homophilic and heterophilic cell adhesion, promoting tumor cell migration and survival. Major players are shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and bispecific constructs. As first-generation therapies reach preclinical and early clinical stages, the next wave of R&D is targeting Nectin-3 to bypass Nectin-4 resistance or address indications with distinct expression profiles. Specifically, highly specific, rapid-internalizing ADCs and bispecific T-cell engagers (e.g., Nectin-3 × CD3) are being developed to overcome tumor microenvironment immunosuppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biopharma Innovators, Preclinical Innovators, Academic Medical Centers | Ovarian Cancer, Breast Cancer, Pancreatic Cancer, NSCLC | Internalization Assay (Requires high-purity ECD-Fc with native glycosylation) |
| Bispecific Antibodies / Engagers (e.g., Nectin-3 × CD3) | Immuno-oncology Startups, Discovery Phase | Solid Tumors, Metastatic Disease, Refractory Solid Tumors | Heterodimer Validation (Requires cross-reactive antibodies and stable target-expressing cell lines) |
| Monoclonal Antibodies (mAb) | Preclinical Research Institutes, Early-stage Biotechs | Adhesion-mediated Metastasis, Metastatic Carcinoma | Selectivity Assay (Requires Nectin-1, Nectin-2, Nectin-3, and Nectin-4 panel proteins) |